Insulinomas are the most common functional pancreatic neuroendocrine tumors (PNETs). They result from the growth of islet cells that produce excess insulin. Insulinomas may be associated with multiple endocrine neoplasia type 1 (MEN1) or Wermer syndrome. Only 10% of insulinomas are malignant (National Cancer Institute [NCI], 2018).
Indications for Testing
- Pancreatic tumor
- Blood glucose ≤40 mg/dL without other etiology
- Hypoglycemia symptoms without other etiology
- Confusion/altered consciousness
- Visual disturbance
Criteria for Diagnosis
- Diagnosis criteria include (North American Neuroendocrine Tumor Society [NANETS], 2010):
- Blood glucose ≤40 mg/dL
- Insulin ≥3 µIU/mL
- C-peptide levels ≥200 pmol/L
- High proinsulin concentration
- Beta-hydroxybutyrate levels ≤2.7 mmol/L
- Absence of sulfonylurea in plasma and urine
- 72-hour observed fast is the gold standard for diagnosis; measure the following:
- Low C-peptide in combination with high insulin: suggestive of surreptitious insulin administration
- Serum/urine sulfonylurea: rule out surreptitious drug-induced hypoglycemia
- Useful immunohistochemistry stains may include synaptophysin and neuron-specific enolase (polyclonal)
- Tumor-specific confirmation: insulin
- For more information, refer to ARUP's Immunohistochemistry Stain Offerings
- Multiphasic computed tomography (CT), magnetic resonance imaging (MRI), or endoscopic ultrasound (EUS) generally can detect most tumors (NCI, 2018)
- Venous drainage catheter localization and calcium stimulation with transhepatic venous sampling are technically challenging and typically not used except in unusual circumstances (NCI, 2018)
- Pancreatic mass
- Other pancreatic neuroendocrine tumor
- Pancreatic adenocarcinoma
- Incidence: 1-32/million (European Neuroendocrine Tumor Society [ENETS] consensus, 2016)
- Median onset: 40s-50s
- Rare in adolescents
- Sex: M<F (minimal)
Genetic: a small percentage are malignant, and these tend to be associated with familial disease (MEN1)
- Generally sporadic
- Majority are benign
- >99% located in the pancreas
- Islet cells (type beta [β]) can develop into hyperplasia, macroadenomas, microadenomas, or malignant adenocarcinomas (almost always pancreatic in location)
- If multiple tumors are present, suspect MEN1
- Only 5-8% of insulinomas are associated with MEN1 (NCI, 2018)
- Symptoms are caused by excess secretion of insulin
- Insulin is synthesized as preproinsulin and released as proinsulin
- With proinsulin release, equal amounts of C-peptide are also released
- Catecholamine excess is common
- Whipple triad
- Neurologic signs/symptoms of hypoglycemia (neuroglycopenia): confusion, headache, sweating, tremor, visual disturbances
- Blood glucose ≤40 mg/dL
- Symptom resolution after glucose ingestion (within 5-10 minutes)
- Other manifestations if a syndromic tumor is present (MEN1): pituitary, pancreatic, and parathyroid tumors
ARUP Laboratory Tests
Qualitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Oberg K, Couvelard A, Delle Fave G, et al. ENETS Consensus Guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology. 2017;105(3):201-211.
Perren A, Couvelard A, Scoazec JY, et al. ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105(3):196-200.
Vinik AI, Woltering EA, Warner RR , et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713-734.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and adrenal tumors. Version 2.2018. [Updated: May 2018; Accessed: May 2018]
Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153-171.
Oberg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii124-130.
Pancreatic neuroendocrine tumors (islet cell tumors) treatment (PDQ) - health professional version. National Cancer Institute. [Updated: Jan 2020; Accessed: Dec 2021]
O'Toole D, Kianmanesh R, Caplin M. ENETS 2016 Consensus Guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology. 2016;103(2):117-118.